Stock Events

Stock Events

Predilife 

€0.6340
3
-€0.16-20.35%Friday 20:55

Statistics

Day High
0.8
Day Low
0.634
52W High
2.2
52W Low
0.562
Volume
0
Avg. Volume
0
Mkt Cap
2.39M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Oct 31Expected
Q3 2024
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-865.11%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
493,000Revenue
-4.27MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap23.86B
Guardant Health specializes in oncology-focused genetic testing, similar to Predilife's cancer prediction tests.
Myriad Genetics
MYGN
Mkt Cap434.25M
Myriad Genetics provides genetic tests for cancer risk, directly competing with Predilife's predictive testing services.
Fulgent Genetics
FLGT
Mkt Cap591.03M
Fulgent Genetics provides comprehensive genetic testing, competing in the same space as Predilife's predictive health tests.
Illumina
ILMN
Mkt Cap35.63B
Illumina manufactures sequencing systems that support cancer genetic testing, indirectly competing with Predilife's services.
Quest Diagnostics
DGX
Mkt Cap25.75B
Quest Diagnostics provides diagnostic testing, including for cancer, which competes with Predilife's predictive testing services.
Labcorp
LH
Mkt Cap22.7B
LabCorp offers a range of healthcare diagnostic tests, including cancer assessments, competing with Predilife's services.
Qiagen NV
QGEN
Mkt Cap9.24B
Qiagen provides sample and assay technologies for molecular diagnostics, including cancer, overlapping with Predilife's market.

About

Founded in 2004 and headquartered in Villejuif, France, Predilife S.A. specializes in devising and commercializing sophisticated medical technologies and analytical models. The company's core offerings include preventative healthcare solutions and comprehensive breast screening tests. Among its notable products are MammoRisk, a diagnostic tool designed to forecast an individual's risk of developing breast cancer; DenSeeMammo, software for evaluating breast tissue density; and a specialized medical device developed for predicting prostate cancer risk.
Show More
CEO
Stephane Ragusa
Employees
21
Country
France
ISIN
FR0010169920
WKN
000A2PBF1

Listings

F
DE
0GA.F
STU
DE
0GA.STU
PA
FR
ALPRE.PA

0 Comments

Share your thoughts

FAQs

What is Predilife stock price today?▼
The current price of 0GA.STU is €0.63 EUR — it has decreased by -20.35% in the past 24 hours. Watch Predilife stock price performance more closely on the chart.
What is Predilife stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Predilife stocks are traded under the ticker 0GA.STU.
What is Predilife market cap?▼
Today Predilife has the market capitalization of 2.39M
When is the next Predilife earnings date?▼
Predilife is going to release the next earnings report on March 3, 2027.
What is Predilife revenue for the last year?▼
Predilife revenue for the last year amounts to 493,000 EUR.
What is Predilife net income for the last year?▼
0GA.STU net income for the last year is -4.27M EUR.
How many employees does Predilife have?▼
As of November 2, 2026, the company has 21 employees.
In which sector is Predilife located?▼
Predilife operates in the Health & Wellness sector.
When did Predilife complete a stock split?▼
Predilife has not had any recent stock splits.
Where is Predilife headquartered?▼
Predilife is headquartered in Villejuif, France.